Background: Enfortumab vedotin (EV) is a standard treatment for metastatic urothelial carcinoma (mUC) after platinum-based chemotherapy and immune checkpoint inhibitors. However, reliable and clinically accessible prognostic tools for patients treated with EV remain limited. We evaluated the clinical prognostic performance of the HERO score in a large real-world cohort of EV-treated patients. Patients and methods: ARON-2EV is a retrospective multicenter cohort study including patients with mUC treated with EV after platinum-based chemotherapy and immune checkpoint inhibitors. The association between the HERO score, based on hemoglobin level and neutrophil-to-lymphocyte ratio, and survival outcomes (overall survival and progression-free survival) was assessed. Response analyses were considered exploratory. Results: A total of 548 patients with mUC treated with EV were included in the analysis. Median overall survival was 12.4 months and median progression-free survival was 6.8 months. The HERO score was associated with survival and response outcomes, with patients with a score of 2 experiencing the most favorable outcomes. These associations remained consistent across multivariable analyses. Conclusions: In this large international real-world cohort, the HERO score was associated with survival and response outcomes in patients with mUC treated with EV, particularly through identification of a subgroup with a more favorable prognosis (score 2). However, discrimination between lower score categories was less pronounced. Further prospective refinement and evaluation of the HERO score are warranted, particularly in contemporary EV-based treatment strategies.

Real-world prognostic assessment of the HERO score in metastatic urothelial carcinoma treated with enfortumab vedotin (ARON-2EV study) / Roviello, G., Ciccimarra, F., Urabe, F., Melichar, B., Studentova, H., Niedersuess-Beke, D., Mota, A., Büttner, T., Gómez de Liaño, A., Yano, A., Myint, Z.W., Kopp, R.M., Zgura, A., Pinto, A., Angel, M., Tural, D., Kanesvaran, R., Ürün, Y., Molina-Cerrillo, J., Marques Monteiro, F.S., et al.. - In: ESMO OPEN. - ISSN 2059-7029. - ELETTRONICO. - 11:(2026), pp. 108302.1-108302.9. [10.1016/j.esmoop.2026.108302]

Real-world prognostic assessment of the HERO score in metastatic urothelial carcinoma treated with enfortumab vedotin (ARON-2EV study)

Roviello, G.;Antonuzzo, L.;
2026

Abstract

Background: Enfortumab vedotin (EV) is a standard treatment for metastatic urothelial carcinoma (mUC) after platinum-based chemotherapy and immune checkpoint inhibitors. However, reliable and clinically accessible prognostic tools for patients treated with EV remain limited. We evaluated the clinical prognostic performance of the HERO score in a large real-world cohort of EV-treated patients. Patients and methods: ARON-2EV is a retrospective multicenter cohort study including patients with mUC treated with EV after platinum-based chemotherapy and immune checkpoint inhibitors. The association between the HERO score, based on hemoglobin level and neutrophil-to-lymphocyte ratio, and survival outcomes (overall survival and progression-free survival) was assessed. Response analyses were considered exploratory. Results: A total of 548 patients with mUC treated with EV were included in the analysis. Median overall survival was 12.4 months and median progression-free survival was 6.8 months. The HERO score was associated with survival and response outcomes, with patients with a score of 2 experiencing the most favorable outcomes. These associations remained consistent across multivariable analyses. Conclusions: In this large international real-world cohort, the HERO score was associated with survival and response outcomes in patients with mUC treated with EV, particularly through identification of a subgroup with a more favorable prognosis (score 2). However, discrimination between lower score categories was less pronounced. Further prospective refinement and evaluation of the HERO score are warranted, particularly in contemporary EV-based treatment strategies.
2026
11
1
9
Goal 3: Good health and well-being
Roviello, G.; Ciccimarra, F.; Urabe, F.; Melichar, B.; Studentova, H.; Niedersuess-Beke, D.; Mota, A.; Büttner, T.; Gómez de Liaño, A.; Yano, A.; Myin...espandi
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S2059702926022441-main.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 460.26 kB
Formato Adobe PDF
460.26 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1499881
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact